ID   HepG2/C3A-2.5B1
AC   CVCL_1N69
SY   C3A clone 2.5B1; Clone 2.5 B1
DR   ATCC; CRL-3533
DR   cancercelllines; CVCL_1N69
DR   Wikidata; Q54808152
RX   Patent=US6653105;
CC   Group: Patented cell line.
CC   Group: Serum/protein free medium cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12461.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1098 ! Hep-G2/C3A
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 19-12-24; Version: 15
//
RX   Patent=US6653105;
RA   Triglia, Dennis
RA   Purchio, Anthony F.
RT   "Clonal cells and cell lines derived from C3A cells and methods of
RT   making and using them.";
RL   Patent number US6653105, 25-Nov-2003.
//